Amsterdam Molecular Therapeutics (AMT) Successfully Raises EUR 5 Million via a Convertible Bond Issue With Shareholder Forbion

Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction.

AMSTERDAM, December 16 - Amsterdam Molecular Therapeutics (NYSE Euronext: AMT), announces today
that it has successfully raised EUR 5 million of new funds via a private
placement of convertible bonds (the "Bonds") to its anchor investor Forbion
Capital Partners of Naarden, The Netherlands. AMT intends to use the net
proceeds from the issue to further strengthen its focused pipeline
development activities in the areas of Hemophilia B, Duchenne Muscular
Dystrophy, Acute Intermittent Porphyria, and Parkinson's Disease. AMT
previously announced that it would be filing for regulatory approval of
its lead product Glybera(R), a gene therapy product to control LipoProtein
Lipase Deficiency (LPLD) no later than February, 2010.

Commenting on the issue, AMT's CEO Jörn Aldag said:

"We are seeing this investment by Forbion as a strong validation of our
scientific and commercial potential and as a sign of trust and confidence in
our company. Based on this financing we now expect to have EUR 22 million of
cash at the end of this year and will be able to fund our pipeline into 2011.
This increases our financial flexibility. We are very happy with this
convertible debt and its terms which upon conversion will strengthen our
equity base."

Further details of the Bonds

The five-year unsecured and unsubordinated Bonds, which have a minimum
denomination of EUR 100,000, have an issue price of 100% and pay an annual
coupon of 5%. During the conversion period, which starts six months after the
funding date (or at the earlier occurrence of a limited number of events,
such as a public offer for AMT) and ends on the final maturity date, the
Bonds are convertible into ordinary shares of AMT at an initial conversion
price of EUR 3,91, representing a conversion premium compared to AMT's
current share price of approximately 30%. The conversion price may be
adjusted in the case of certain dilutive events. During the conversion period
AMT has the option to call the conversion of the Bonds if AMT's share price
exceeds 150% of the then prevailing conversion price for a period of at least
ten consecutive trading days. Funds managed by Forbion Capital Partners shall
be the initial holders of the tradable Bonds. The Bonds will not be listed.

Kempen & Co acted as financial advisor to AMT.

About Amsterdam Molecular Therapeutics

AMT, founded in 1998 and based in Amsterdam, is a leader in the
development of human gene based therapies. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV production platform. This safe and efficacious proprietary
platform offers a unique manufacturing capability which can be applied to a
large number of rare (orphan) diseases that are caused by one faulty gene.
Currently, AMT has a product pipeline with several AAV-based gene therapy
products in LPL Deficiency, Hemophilia B, Duchenne Muscular Dystrophy, Acute
Intermittent Porphyria and Parkinson's Disease at different stages of
research or development.

Not for distribution, directly or indirectly, in or into the United
States, Australia, Canada, Japan or South Africa or to US persons. This
announcement is not a prospectus and does not contain or constitute an offer
for sale or the solicitation of an offer to purchase securities in the United
States, Canada, South Africa, Australia, Japan or any other jurisdiction.

The securities mentioned herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and
may not be offered or sold in the United States absent registration under the
Securities Act or an available exemption from, or transaction not subject to,
the registration requirements of the Securities Act

Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues,"
"estimates," "intends," "projects," "goals," "targets" and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on
these statements because, by their nature, they are subject to known and
unknown risks and can be affected by factors that are beyond the control of
AMT. Actual results could differ materially from current expectations due to
a number of factors and uncertainties affecting AMT's business, including,
but not limited to, the timely commencement and success of AMT's clinical
trials and research endeavors, delays in receiving U.S. Food and Drug
Administration or other regulatory approvals (i.e. EMEA, Health Canada),
market acceptance of AMT's products, effectiveness of AMT's marketing and
sales efforts, development of competing therapies and/or technologies, the
terms of any future strategic alliances, the need for additional capital, the
inability to obtain, or meet, conditions imposed for required governmental
and regulatory approvals and consents. AMT expressly disclaims any intent or
obligation to update these forward-looking statements except as required by
law. For a more detailed description of the risk factors and uncertainties
affecting AMT, refer to the prospectus of AMT's initial public offering on
June 20, 2007, and AMT's public announcements made from time to time.

For information: Jörn Aldag, Chief Executive Officer, Tel +31(0)20-566-7394, j.aldag at amtbiopharma.com